Advicenne Launches IPO With Kidney Drug Close To Filing
Looking to raise up to €39.7m through a stock market listing, French firm Advicenne has been developing ADV7103, which could soon become the first drug to be approved for distal renal tubular acidosis.
You may also be interested in...
Having had a bid for accelerated assessment rejected by the EMA last year, the French biotech is getting a standard review for ADV7103 in dRTA patients and hopes to launch late 2020.
The first half of the year was pretty bleak for companies seeking fast-track review of their products in the EU. There has been much better news in the second half. The Pink Sheet tracks the winners and losers.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.